2024
Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer
Shan N, Gould B, Wang X, Bonora G, Blenman K, Foldi J, Campos G, Walsh M, Du P, Pusztai L. Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer. The Journal Of Liquid Biopsy 2024, 6: 100168. DOI: 10.1016/j.jlb.2024.100168.Peer-Reviewed Original ResearchTriple negative breast cancerResidual cancer burdenCirculating tumor DNANegative breast cancerPathological responsePost-NACBreast cancerPlasma circulating tumor DNATriple negative breast cancer patientsResidual cancer burden scoreCirculating tumour DNA fractionPost-neoadjuvant chemotherapyPre-NAC samplesWeekly nab-paclitaxelTumor DNA methylation profilesTumor DNA fractionHot spot mutationsYouden's J statisticNab-paclitaxelPre-NACTumor variantsTumor DNATumor fractionClinical trialsDNA methylation profiles
2018
Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo
Shin S, Jeong B, Wall B, Li J, Shan N, Wen Y, Goydos J, Chen S. Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo. Oncogenesis 2018, 7: 86. PMID: 30425240, PMCID: PMC6234219, DOI: 10.1038/s41389-018-0098-7.Peer-Reviewed Original ResearchMelanoma cell proliferationCell proliferationXCT expressionPhase II clinical trialDose-dependent decreasePost-treatment specimensTumor biopsy samplesXenograft-bearing animalsMelanoma cell growthHuman melanoma cell linesHuman tumor biopsy samplesCultured human melanomaStable diseaseMelanoma cell linesAggressive tumorsCancer stageClinical trialsTumor biopsiesXenograft studiesRiluzoleBiopsy samplesMost melanomasHuman melanomaTumor progressionWestern immunoblot analysis